The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The Mindset-01 Phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting multiple sclerosis. The fifteen month trial is fully enrolled with 218 patients at 24 sites in six countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.